DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
12 nov. 2018 16h45 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 12, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list...
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
06 nov. 2018 17h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual...
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
05 sept. 2018 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as...
DiaMedica Issues Stock Option Grant
23 août 2018 19h30 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and...
DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
03 mai 2018 08h30 HE
|
DiaMedica Therapeutics Inc.
DiaMedica has received final minutes from Type B meeting with the US FDADiaMedica preparing to submit an IND to initiate DM199 clinical study in patients with chronic kidney disease in the US ...
DiaMedica Issues Stock Option Grants
17 avr. 2018 21h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 17, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX-V:DMA) (OTCQB:DMCAF), today announced the issuance of 2,551,000 stock options to various officers and...
DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
05 avr. 2018 07h15 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial...
DiaMedica Therapeutics Announces Final Closing of Private Placement
29 mars 2018 18h08 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...